|
Colorectal Carcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Allergic Reaction
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Eleven loci with new reproducible genetic associations with allergic disease risk.
|
29679657 |
2019 |
|
Aspartate aminotransferase measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Serum aspartate aminotransferase and alanine aminotransferase levels were higher in the STAM group than in the normal group (non-NASH-induced mice).
|
31155606 |
2019 |
|
Fatty Liver Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
In the present study, diabetic nonalcoholic steatohepatitis (NASH) mice (STAM mice) received daily administrations of telmisartan for 6 weeks to assess the improvements in NASH.
|
30850637 |
2019 |
|
Fatty Liver Disease
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Gemcabene was evaluated in the STAM™ murine model of NASH.
|
29847555 |
2018 |
|
Fatty Liver Disease
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
To experimentally validate this hypothesis, we tested a small-molecule inhibitor of the BET family of proteins, GSK1210151A (I-BET151), in the STAM mouse NASH model at two different dosing timepoints (onset of NASH and progression to fibrosis).
|
30467325 |
2018 |
|
Fatty Liver Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
STAM mice may be a useful model for elucidating the pathogenesis of NASH with diabetes.
|
28730823 |
2017 |
|
Fatty Liver Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
In addition, proteome analysis of liver tumors in male STAM NASH-model mice was performed.
|
28218651 |
2017 |
|
Fatty Liver Disease
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
To reveal the molecular mechanism underlying hepatocarcinogenesis from NASH, microRNA (miRNA) expression profiles were analyzed in STAM mice, a NASH-HCC animal model.
|
25117675 |
2014 |
|
Steatohepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Histological analysis revealed that STAM mice had fatty liver, NASH, and fibrosis at 6, 8, and 10 weeks, respectively.
|
31155606 |
2019 |
|
Steatohepatitis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
STAM mice treated with INK-128 presented abrogated mTOR expression and tumour progression under hypoxic conditions with lower triglycerides and steatosis.
|
31796646 |
2019 |
|
Steatohepatitis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Histopathological images of the liver of STAM mice at the ages of 6, 8, 12, and 18 weeks showed findings compatible with fatty liver, NASH, liver cirrhosis (LC), and HCC, respectively.
|
25117675 |
2014 |
|
Fatty Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histological analysis revealed that STAM mice had fatty liver, NASH, and fibrosis at 6, 8, and 10 weeks, respectively.
|
31155606 |
2019 |
|
Hyperglycemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Similar sex-independent HCC occurred in the "STAM" model of mice, in which severe hyperglycemia and HF feeding results in rapid hepatic lipid deposition, fibrosis, and ultimately HCC.
|
31575546 |
2019 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Similar sex-independent HCC occurred in the "STAM" model of mice, in which severe hyperglycemia and HF feeding results in rapid hepatic lipid deposition, fibrosis, and ultimately HCC.
|
31575546 |
2019 |
|
Hepatocarcinogenesis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice.
|
30194503 |
2018 |
|
Hyperglycemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggested that the increase in oxidative stress with hyperglycemia triggered hepatic lesions in STAM mice, and insulin resistance promoted lesion formation with hepatic lipid accumulation.
|
28730823 |
2017 |
|
Fatty Liver
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Histopathological images of the liver of STAM mice at the ages of 6, 8, 12, and 18 weeks showed findings compatible with fatty liver, NASH, liver cirrhosis (LC), and HCC, respectively.
|
25117675 |
2014 |
|
Hepatocarcinogenesis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
To reveal the molecular mechanism underlying hepatocarcinogenesis from NASH, microRNA (miRNA) expression profiles were analyzed in STAM mice, a NASH-HCC animal model.
|
25117675 |
2014 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histopathological images of the liver of STAM mice at the ages of 6, 8, 12, and 18 weeks showed findings compatible with fatty liver, NASH, liver cirrhosis (LC), and HCC, respectively.
|
25117675 |
2014 |
|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
Suppression of EGFR ubiquitination by site-directed mutagenesis or by knocking down two EGFR-sorting molecules, signal-transducing adaptor molecule (STAM) and lysosomal protein transmembrane 4 β (LAPTM4B), suggested that EGFR transport to the late endosome is critical for efficient HBV infection.
|
31836663 |
2020 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
STAM mice treated with INK-128 presented abrogated mTOR expression and tumour progression under hypoxic conditions with lower triglycerides and steatosis.
|
31796646 |
2019 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
We demonstrate that NV556 decreased liver fibrosis in both STAM and MCD in vivo models and decreased collagen production in TGFβ1-activated hepatic stellate cells in vitro.
|
31717385 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the STAM model, Namodenoson significantly decreased the non‑alcoholic fatty liver disease (NAFLD) activity score, NAS, demonstrating anti‑inflammatory and anti‑steatotic effects.
|
31638172 |
2019 |